Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.37 |
| ▸ | BTN3A1 | O00481 | 8/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120052 | 0.94 | CYP3A4 (0.45) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL17719213 | 0.94 | CYP3A4 (0.45) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL17719206 | 0.94 | CYP3A4 (0.38) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL25510132 | 0.94 | CYP3A4 (0.38) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL10120054 | 0.94 | CYP3A4 (0.38) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL29578011 | 0.94 | CYP3A4 (0.38) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL10120050 | 0.94 | CYP3A4 (0.40) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL17719207 | 0.93 | TMPRSS2 (0.37) | CYP3A4CYP2C9TMPRSS2 | |
| SCHEMBL17719201 | 0.91 | CYP3A4 (0.37) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL25510085 | 0.91 | CYP3A4 (0.37) | CYP3A4CYP2C9TMPRSS2BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20150152116-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | CYP3A4 1697/4885CYP2C9 3257/4885TMPRSS2 433/4885 |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | CYP3A4 1697/4885CYP2C9 3257/4885TMPRSS2 433/4885 |
| US-20150152116-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | CYP3A4 1697/4885CYP2C9 3257/4885TMPRSS2 433/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | CYP3A4 1697/4885CYP2C9 3257/4885TMPRSS2 433/4885 |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | ACE2, ACE, PNP | CYP3A4 296/4885CYP2C9 476/4885TMPRSS2 6/4885 |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885TMPRSS2 12/4885 |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | ACE2, ACE, PNP | CYP3A4 296/4885CYP2C9 476/4885TMPRSS2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.